The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...

Kennedy has been criticized for making false medical claims. He has also vowed to purge the U.S. Food and Drug Administration ...

They say RFK Jr. would threaten the achievements - including combating deadly diseases and monitoring drug safety - of a science-based public health order painstakingly built since World War II.

EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma: Paris Saturday, November 16, 2024, 09:00 H ...

Manila Water Foundation Joins Erceflora Probiotics and Save the Children Philippines to Expand Hygiene and Water Access for ...

AstraZeneca and GSK fell as the president-elect named Kennedy as his pick for the role overseeing the US's rules on medicine, ...

Shares in global vaccine makers fell sharply on Friday (November 15).Markets were spooked by U.S. President-elect Donald ...

Deutsche Bank downgraded GSK (GSK) to Hold from Buy with a price target of 1,350 GBp, down from 1,700 GBp. The firm cites President-elect ...

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

(Reuters) -Shares in global vaccine makers and drugmakers fell on Friday after U.S. President-elect Donald Trump picked ...